Laurus Labs - Public Comps and Valuation Multiples

Laurus Labs Overview

About Laurus Labs

Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.

Founded

2005

HQ

Employees

6.2K+

Website

lauruslabs.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $703M

LTM EBITDA $161M

EV

$6.4B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Laurus Labs Financials

As of November 2025, Laurus Labs reported last 12-month revenue of $703M and EBITDA of $161M.

In the same period, Laurus Labs generated $404M in LTM gross profit and $67.9M in net income.

See Laurus Labs valuation multiples based on analyst estimates

Laurus Labs P&L

In the most recent fiscal year, Laurus Labs reported revenue of $616M and EBITDA of $125M.

Laurus Labs expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Laurus Labs valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$703M	XXX	$616M	XXX	XXX	XXX
Gross Profit	$404M	XXX	$332M	XXX	XXX	XXX
Gross Margin	57%	XXX	54%	XXX	XXX	XXX
EBITDA	$161M	XXX	$125M	XXX	XXX	XXX
EBITDA Margin	23%	XXX	20%	XXX	XXX	XXX
EBIT	$111M	XXX	$70.0M	XXX	XXX	XXX
EBIT Margin	16%	XXX	11%	XXX	XXX	XXX
Net Profit	$67.9M	XXX	$40.1M	XXX	XXX	XXX
Net Margin	10%	XXX	7%	XXX	XXX	XXX
Net Debt	XXX	XXX	$290M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Laurus Labs including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $703M. EBITDA for the last twelve months was $161M. In the most recent fiscal year, Laurus Labs achieved $616M in revenue and $125M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$703M	Analyst estimates available to subscribers	$616M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$404M	Analyst estimates available to subscribers	$332M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	57.4% gross margin	Analyst estimates available to subscribers	53.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$161M	Analyst estimates available to subscribers	$125M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	23.0% EBITDA margin	Analyst estimates available to subscribers	20.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$111M	Analyst estimates available to subscribers	$70.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	15.7% EBIT margin	Analyst estimates available to subscribers	11.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$67.9M	Analyst estimates available to subscribers	$40.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	9.7% net profit margin	Analyst estimates available to subscribers	6.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$290M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Laurus Labs

This financial data table provides comprehensive performance metrics for Laurus Labs, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Laurus Labs generated $703M in revenue over the last twelve months.
The company achieved $161M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $404M.
Net income over the last twelve months reached $67.9M.

Fiscal Year Performance

In the most recent fiscal year, Laurus Labs reported $616M in total revenue.
Fiscal year EBITDA was $125M.
The company maintained a gross profit margin of 53.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was 20.4%.
Net profit margin reached 6.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Laurus Labs. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Laurus Labs Stock Performance

Laurus Labs has current market cap of INR 550B (or $6.2B), and EV of INR 572B (or $6.4B).

Market Cap Evolution

Laurus Labs Stock Data

As of December 3, 2025, Laurus Labs's stock price is INR 1020 (or $11).

See Laurus Labs trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$6.4B	$6.2B	XXX	XXX	XXX	XXX	$0.13

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Laurus Labs Valuation Multiples

Laurus Labs's trades at 10.6x EV/Revenue multiple, and 55.0x EV/EBITDA.

See valuation multiples for Laurus Labs and 15K+ public comps

Laurus Labs Financial Valuation Multiples

As of December 3, 2025, Laurus Labs has market cap of $6.2B and EV of $6.4B.

Equity research analysts estimate Laurus Labs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Laurus Labs has a P/E ratio of 90.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$6.2B	XXX	$6.2B	XXX	XXX	XXX
EV (current)	$6.4B	XXX	$6.4B	XXX	XXX	XXX
EV/Revenue	9.1x	XXX	10.6x	XXX	XXX	XXX
EV/EBITDA	39.7x	XXX	55.0x	XXX	XXX	XXX
EV/EBIT	57.9x	XXX	100.8x	XXX	XXX	XXX
EV/Gross Profit	15.9x	XXX	n/a	XXX	XXX	XXX
P/E	90.7x	XXX	178.2x	XXX	XXX	XXX
EV/FCF	287.7x	XXX	-1750.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Laurus Labs Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Laurus Labs Margins & Growth Rates

Laurus Labs's last 12 month revenue growth is 17%

Laurus Labs's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $43K for the same period.

Laurus Labs's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Laurus Labs's rule of X is 65% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Laurus Labs and other 15K+ public comps

Laurus Labs Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	17%	XXX	17%	XXX	XXX	XXX
EBITDA Margin	23%	XXX	19%	XXX	XXX	XXX
EBITDA Growth	30%	XXX	35%	XXX	XXX	XXX
Rule of 40	36%	XXX	36%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	65%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$43K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	43%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial